Protocol 1 / 6
Protocol 1: Intravenous Mesenchymal Stem Cell (IV MSC) Infusion
A systemic infusion of mesenchymal stem cells (MSCs) delivered through a peripheral IV line. The MSCs travel throughout the body and exert immunomodulatory, anti-inflammatory, and paracrine effects most relevant for autoimmune conditions, post-viral recovery, neurological inflammation, and integrative anti-aging strategies.
Indications
- · Autoimmune conditions (rheumatoid arthritis, lupus, Crohn's, ulcerative colitis, Sjögren's, Hashimoto's)
- · Anti-aging and longevity support in patients with no active malignancy and no active autoimmune flare
- · Post-COVID / long-COVID inflammation with persistent fatigue and cognitive symptoms
- · Multiple sclerosis and other neuro-inflammatory conditions (adjunctive, not curative)
- · Generalized chronic inflammation documented by hsCRP / IL-6 elevation
Pre-procedure preparation
- · Baseline labs: complete blood count (CBC), comprehensive metabolic panel (CMP), high-sensitivity C-reactive protein (hsCRP), HbA1c, vitamin D 25-OH, lipid panel, TSH
- · Hydration: 1.5–2 L of water in the 24 hours before the infusion, avoid alcohol for 48 hours
- · Medication review with the treating physician — anticoagulants and immunosuppressants are evaluated individually
- · NSAIDs (ibuprofen, naproxen, diclofenac) avoided for at least 48 hours prior unless medically necessary
- · Written informed consent reviewed and signed in advance per NOM-004-SSA3-2012
Procedure
- 01. Vital signs baseline (blood pressure, heart rate, oxygen saturation, temperature) recorded by clinical staff
- 02. Peripheral IV cannula placed in the antecubital or forearm vein under sterile technique
- 03. MSC dose 100–150 million cells (typical adult range) suspended in physiologic saline
- 04. Infusion delivered slowly over 60–90 minutes with continuous vital-sign monitoring
- 05. Treating physician available throughout the session for symptom check-ins
Post-procedure care
- · Observation period of 30 minutes after the line is removed
- · Avoid NSAIDs for 24 hours so the immunomodulatory signal is not blunted
- · Gentle hydration (water, electrolytes) for the rest of the day
- · Light activity only on day 1 (walking is fine, no intense workouts)
- · Sleep hygiene encouraged the night of infusion — MSC distribution and signaling continues over 24–72 hours
Follow-up schedule
- · Week 6 — symptom check-in by WhatsApp or video, repeat hsCRP if baseline was elevated
- · Week 12 — clinical review and outcome scales relevant to the indication (e.g. DAS28 for rheumatoid arthritis, FACIT-Fatigue for long-COVID)
- · Week 24 — long-term outcome review, decision on maintenance protocols if indicated
Risks and possible side effects
- · Transient low-grade fever in the 24 hours post-infusion (uncommon, self-limited)
- · Mild fatigue or flu-like sensation for 24–48 hours
- · Headache and mild nausea (rare)
- · Local IV-site reaction (bruising, soreness)
- · Pulmonary embolism risk is exceptionally rare with infusion-grade MSCs (<0.1% in published series), screened for by pre-procedure risk assessment
- Duration of visit
- Approximately 3 hours total visit (intake, infusion, observation)
- Cost range
- $7,000–$22,000 USD depending on cell dose and add-ons (NAD+, vitamin cocktail, exosomes)
Protocol 2 / 6
Protocol 2: Intra-articular MSC + PRP (Joint Protocol)
An image-guided injection of mesenchymal stem cells combined with platelet-rich plasma directly into the affected joint. Targets the synovial environment and cartilage of patients with moderate osteoarthritis or persistent joint pain who have not responded fully to conservative care.
Indications
- · Knee osteoarthritis Kellgren-Lawrence grade II–III
- · Shoulder osteoarthritis with intact rotator-cuff anatomy
- · Hip osteoarthritis grade II–III with preserved joint space
- · Facet joint osteoarthritis of the lumbar or cervical spine
- · Persistent joint pain after failed conservative therapy (PT, NSAIDs, intra-articular corticosteroids)
Pre-procedure preparation
- · Recent imaging review: MRI (preferred) and weight-bearing X-rays of the index joint
- · Targeted physical exam with range-of-motion documentation
- · WOMAC (Western Ontario and McMaster) score recorded at baseline for outcome tracking
- · NSAIDs and intra-articular corticosteroids avoided for 5–7 days before the injection unless medically necessary
- · Skin over the target joint inspected for infection or active dermatitis
Procedure
- 01. Joint and surrounding skin prepped with chlorhexidine under sterile technique
- 02. Ultrasound (knee, shoulder, hip) or fluoroscopy (facet joints) used for real-time needle guidance
- 03. MSC dose 20–30 million cells combined with autologous platelet-rich plasma (PRP)
- 04. Slow intra-articular delivery with confirmation of correct needle placement on imaging
- 05. Local anesthesia at skin level; the intra-articular space itself is not anesthetized to preserve cell viability
Post-procedure care
- · 24 hours of relative rest, ice 15 minutes every 2–3 hours over the joint
- · NSAIDs avoided for at least 7 days post-injection to preserve the inflammatory healing signal
- · Gradual mobilization in weeks 1–2 with pain as the limit
- · Return to low-impact activity weeks 2–4, sport-specific progression weeks 4–8
- · Physical therapy coordinated remotely or in-person to reinforce gains
Follow-up schedule
- · Week 6 — clinical review and WOMAC re-score
- · Week 12 — WOMAC, functional testing, decision on a second dose if response is partial
- · Week 24 — WOMAC long-term outcome
- · Month 12 — repeat imaging if clinically indicated by persistent symptoms
Risks and possible side effects
- · Transient post-injection swelling and stiffness for 48–72 hours
- · Mild flare of pain in the first week as the inflammatory healing signal is generated
- · Rare joint infection (<0.1% under sterile image-guided technique)
- · Bruising at the needle entry point
- Duration of visit
- Approximately 90 minutes (intake, preparation, injection, observation)
- Cost range
- $7,000–$12,000 USD per joint
Protocol 3 / 6
Protocol 3: Intradiscal MSC (Spine Protocol)
A fluoroscopy-guided injection of mesenchymal stem cells into a degenerative intervertebral disc, often combined with a transforaminal MSC component when there is associated radiculopathy. Indicated for patients with documented Pfirrmann II–III disc degeneration who have failed conservative care.
Indications
- · Pfirrmann II–III lumbar or cervical disc degeneration documented on MRI
- · Contained disc herniation without sequestered fragment
- · Persistent axial back pain after failed conservative therapy (PT, epidural injections, activity modification)
- · Discogenic pain confirmed by clinical pattern and imaging correlation
- · Selected cases of radiculopathy when the symptomatic level matches the imaging finding
Pre-procedure preparation
- · Recent spine MRI (within 6 months) reviewed by the treating physician
- · Neurological exam — strength, sensation, deep tendon reflexes — documented
- · Red flags ruled out: cauda equina syndrome, significant motor deficit, malignancy, untreated infection, unexplained weight loss
- · Oswestry Disability Index (ODI) recorded at baseline
- · Anticoagulants and NSAIDs avoided 5–7 days prior unless medically necessary
- · Conscious sedation planning if requested by the patient and approved by the physician
Procedure
- 01. Patient positioned prone, fluoroscopy unit confirmed and surgical pause performed
- 02. Skin prepped with chlorhexidine; sterile drape applied
- 03. Local anesthetic to the skin and subcutaneous track
- 04. 22G or 25G spinal needle advanced under fluoroscopy guidance into the index disc
- 05. MSC suspension delivered intradiscally; a transforaminal MSC component is added at the symptomatic root when there is radiculopathy
- 06. Imaging documentation of needle position and contrast spread before and after delivery
Post-procedure care
- · 24 hours of relative bed rest with bathroom privileges; no driving for 24 hours
- · Gentle ambulation starting day 2; no prolonged sitting >30 minutes for the first week
- · Avoid bending, lifting, twisting (BLT precautions) for 2 weeks
- · NSAIDs avoided for 7 days to preserve the regenerative signal
- · Physical therapy starts week 2–6 with a graduated McKenzie-based or stabilization protocol
Follow-up schedule
- · Week 6 — clinical review, ODI re-score, pain scale
- · Week 12 — ODI long-term, functional testing, decision on maintenance
- · Month 12 — repeat MRI if symptoms persist or to document disc hydration changes
Risks and possible side effects
- · Transient discitis-like reaction (sterile inflammation) in the first 1–2 weeks, presenting as a brief increase in pain that resolves with conservative care
- · Discitis (true infection) is rare under sterile fluoroscopy-guided technique (<0.1%)
- · Bruising or soreness at the needle entry point
- · Vasovagal response during the procedure (managed with hydration and position)
- · Worsening of pain in a small subset of patients — discussed openly during informed consent
- Duration of visit
- Approximately 2 hours total visit (intake, fluoroscopy procedure, observation)
- Cost range
- $9,000–$15,000 USD
Protocol 4 / 6
Protocol 4: PRP-only (Sports / Hair / Sexual Wellness)
Autologous platelet-rich plasma prepared from the patient's own blood and applied to the target tissue. Indicated for tendinopathy, mild osteoarthritis, androgenetic alopecia, and selected sexual wellness applications. Single-session protocols are common, with several sessions for hair and aesthetic protocols.
Indications
- · Lateral and medial epicondylitis (tennis elbow / golfer's elbow), patellar tendinopathy, Achilles tendinopathy
- · Rotator cuff tendinopathy without full-thickness tear
- · Mild osteoarthritis grade I–II as a more conservative option than MSC
- · Androgenetic alopecia and post-transplant scalp support
- · Erectile dysfunction Grade I–II as an adjunct to lifestyle modification and medical optimization
Pre-procedure preparation
- · Targeted blood draw on the day of treatment (no fasting required)
- · Condition-specific evaluation: physical exam for sports indications, trichoscopy for hair, IIEF-5 for ED
- · NSAIDs avoided for 5–7 days prior so the PRP-driven inflammatory signal is not blunted
- · Anticoagulants reviewed individually with the treating physician
- · Skin cleansing of the target area; for scalp protocols hair is washed without conditioner
Procedure
- 01. Venous blood collected into citrate tubes
- 02. Centrifuge cycle of approximately 15 minutes to separate the buffy-coat layer
- 03. Leukocyte-rich PRP (LR-PRP) for tendinopathy and joints with documented degeneration; leukocyte-poor PRP (LP-PRP) for aesthetic, hair, and ED protocols
- 04. Condition-specific delivery: ultrasound-guided intra-tendinous, intra-articular, or peri-tendinous for sports; mesotherapy pattern across the scalp for hair; targeted infiltration for ED
- 05. Sessions repeated as part of the prescribed cycle (commonly 3–6 sessions, 3–6 weeks apart)
Post-procedure care
- · NSAIDs avoided for 24 hours minimum, ideally 7 days
- · Condition-specific care: 48 hours of relative rest for tendons, no heat or hair products for 24 hours after scalp PRP, no sexual activity for 24–48 hours after ED protocols
- · Mild discomfort at the injection site is expected and resolves within 24–48 hours
- · Gentle return to activity per condition-specific guidance
Follow-up schedule
- · Weekly self-tracking of pain or condition-specific scales for the first cycle
- · Mid-cycle clinical check (typically week 4–6)
- · End-of-cycle review with photographic or imaging documentation when relevant
Risks and possible side effects
- · Local discomfort and bruising at the injection site (common, self-limited)
- · Transient flare of pain in the 24–72 hours after a tendon or joint injection
- · Scalp tenderness for 24 hours after hair PRP
- · Risks from PRP itself are minimal because the product is autologous
- Duration of visit
- Approximately 1 hour per session
- Cost range
- $400–$1,500 USD per session, depending on the indication, the preparation kit, and whether ultrasound guidance is used
Protocol 5 / 6
Protocol 5: Peptide Therapy
A class of small-protein therapies prescribed and supervised by a licensed physician. Peptides are selected based on the patient's goals, current biomarkers, and contraindications. Most cycles run 3–6 months with monthly clinical check-ins and quarterly labs.
Indications
- · BPC-157 — connective tissue support, gastrointestinal indications, soft-tissue recovery (off-label, physician-supervised)
- · TB-500 (thymosin beta-4) — soft tissue recovery support
- · CJC-1295 / Ipamorelin — growth hormone axis support for selected anti-aging cycles
- · PT-141 (bremelanotide) — sexual wellness for selected female and male patients
- · Sermorelin — secondary growth hormone release modulation
- · GHK-Cu — skin and hair support, integrated into aesthetic protocols
Pre-procedure preparation
- · Full medical evaluation with the treating physician
- · Baseline labs: CBC, CMP, lipid panel, IGF-1, fasting glucose, HbA1c, sex hormones if relevant, vitamin D, thyroid panel
- · Contraindication screening: active or recent malignancy, untreated hormonal disorder, pregnancy or lactation, retinopathy for growth-axis peptides
- · Disclosure of all current medications and supplements, including over-the-counter products
- · Written informed consent that includes the off-label nature of certain peptide indications
Procedure
- 01. Subcutaneous self-administration in the abdomen or thigh for most cycles, with detailed video and written instruction provided
- 02. Supervised intramuscular or IV administration in clinic for selected protocols
- 03. Frequency: typically daily for the first 4–6 weeks of a cycle, then a 2–3x weekly maintenance phase, or a 5-on / 2-off pattern depending on the peptide
- 04. Cycle duration: 3–6 months as the standard, with a planned wash-out period before repeating
- 05. Storage and reconstitution instructions provided in writing — bacteriostatic water, refrigerated, in-date
Post-procedure care
- · Track injection-site reaction, sleep, energy, and condition-specific markers in a simple log
- · Hydration and a clean nutrition baseline support the peptide effect
- · Avoid alcohol on injection days for growth-axis peptides
- · Report any unexpected symptom to the treating physician within 24 hours
Follow-up schedule
- · Monthly clinical check-in by video call
- · Quarterly labs to re-test the baseline panel and adjust the cycle
- · End-of-cycle review with a written plan for maintenance, wash-out, or transition to a different peptide
Risks and possible side effects
- · Injection-site reaction (redness, mild swelling, transient itching)
- · Headache or flushing in the first week of certain peptides
- · Individual sensitivities — any new symptom is reported to the physician
- · Off-label use means peptide therapy is delivered under physician supervision with informed consent, not as a guaranteed clinical pathway
- · Pregnancy, lactation, and active malignancy are absolute contraindications for most peptide cycles
- Duration of visit
- Initial setup visit 60–90 minutes; subsequent doses self-administered at home
- Cost range
- $400–$1,800 USD per cycle depending on peptide selection, duration, and supervision intensity
Protocol 6 / 6
Protocol 6: Combination Protocols (Anti-aging Stack)
A multi-week program that combines IV mesenchymal stem cells, intravenous NAD+, a customized vitamin cocktail, a peptide cycle, and structured lifestyle coaching. Designed for patients without active malignancy or active autoimmune flare who are looking for an integrated longevity protocol.
Components
- · IV mesenchymal stem cell infusion (Protocol 1) — single dose at week 2
- · IV NAD+ — 250–750 mg per session, escalating dose over weeks 3–4
- · IV vitamin cocktail — magnesium, B-complex, vitamin C, glutathione, customized to baseline labs
- · Peptide stack — selected from BPC-157, CJC/Ipamorelin, GHK-Cu, or others depending on goals
- · Lifestyle coaching — sleep, nutrition, training, stress, supplement layering
Pre-procedure preparation
- · Comprehensive labs (CBC, CMP, lipid panel, HbA1c, hsCRP, vitamin D, IGF-1, thyroid, sex hormones if relevant)
- · Cardiology clearance if there is any cardiovascular history
- · Cancer screening up to date for age and sex (mammogram, colonoscopy, PSA, dermatology screen as relevant)
- · Written informed consent that documents each component of the stack
Sequencing
- 01. Week 1 — baseline labs, full medical evaluation, written protocol design and informed consent
- 02. Week 2 — IV MSC infusion (Protocol 1) with full pre/post protocol
- 03. Week 3 — IV NAD+ session 1 (low starting dose, vital monitoring)
- 04. Week 4 — IV NAD+ session 2 with adjusted dose; IV vitamin cocktail session 1
- 05. Weeks 5–12 — peptide cycle initiated, monthly clinical check-ins, optional IV vitamin maintenance
- 06. Week 12 — full re-evaluation, repeat labs, written maintenance plan
Follow-up schedule
- · Monthly clinical check-ins during the peptide cycle
- · Quarterly labs through the full year following the program
- · Annual re-evaluation with documented outcome metrics
Risks and possible side effects
- · Each component carries the risk profile described in its own protocol — risks compound only modestly because the protocols are sequenced, not stacked on a single day
- · NAD+ infusions can cause transient flushing, chest pressure, or nausea controlled by slowing the infusion
- · Active malignancy or untreated autoimmune flare are absolute contraindications
- Duration of visit
- Approximately 12 weeks of active treatment, with a 12-month maintenance and follow-up tail
- Cost range
- $14,000–$30,000 USD for the full program
Frequently asked questions about our protocols
Transparency. Patients deserve to understand the framework a physician will draw from when designing their personalized plan. Publishing the protocols lets you see the typical pre-procedure preparation, the equipment used (ultrasound, fluoroscopy), the cell doses we work within, the follow-up cadence, and the risk profile of each protocol. Your actual plan will still be individualized to your case, but you walk into the consultation already knowing the shape of regenerative care at our clinic.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
No. Mesenchymal stem cell therapy, PRP, exosome therapy, and peptide protocols are supportive and evolving therapies. Outcomes vary by patient, by indication, by stage of the underlying condition, and by adherence to the post-procedure plan. COFEPRIS advertising rules explicitly prohibit guaranteed-outcome claims for medical procedures, and any clinic that offers one is operating outside the regulatory framework. We document the published evidence for each protocol during your consultation so your expectations are calibrated to the data.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
All cellular products applied at Regeneris are sourced from COFEPRIS-registered Mexican laboratories with documented donor screening (HIV, HBV, HCV, syphilis, HTLV, CMV, plus genetic and hereditary disease screening), cell viability and surface marker characterization (CD90+, CD73+, CD105+), and a documented chain of custody. We can name the supplying laboratory in writing on request and provide the Certificate of Analysis for the lot used in your protocol.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Most allogeneic mesenchymal stem cell preparations are not FDA-approved as drugs in the United States — they sit inside the FDA's IND (Investigational New Drug) pathway and may only be administered inside registered clinical trials in the US. The FDA framework does not apply outside US jurisdiction. In Mexico, equivalent products are administered under COFEPRIS-regulated medical practice provided the clinic, laboratory, and physician all hold the correct authorizations. Our regulatory page documents each authorization with verifiable numbers.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Often yes, but it requires individualized planning. Combining systemic and local protocols is common in our anti-aging stack and in the integrated treatment of certain orthopedic patients with concurrent inflammatory drivers. The treating physician sequences the protocols rather than stacking them on a single day, so each component carries its own safety margin. The combination is documented in your written treatment plan and informed consent before any payment.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Every protocol at Regeneris requires written informed consent per Mexican law (NOM-004-SSA3-2012). The consent document lists the protocol selected, the indication, the dose, the route of administration, the expected post-procedure care, the documented risks, the alternatives considered, and the off-label nature of any component when applicable. The document is reviewed with the physician, questions are answered, and the patient signs before any payment for the procedure itself.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Educational reference only. The protocols described on this page are typical procedural shapes drawn from current evidence and our clinical practice. Each patient receives an individualized treatment plan after a complete medical evaluation. No protocol on this page constitutes a personalized medical recommendation, a guarantee of outcome, or a substitute for the clinical relationship with your treating physician. All procedures at Regeneris Therapy are performed under COFEPRIS-regulated authorizations and with written informed consent per NOM-004-SSA3-2012.